Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
President Wee Kim Wee accepted her plea for clemency in 1992 and her death sentence was commuted to life imprisonment; her two accomplices, however, were executed in 1992. While serving her life sentence, she was diagnosed with cervical cancer in 1993 and had at most a year to live. She appealed to President Ong Teng Cheong for clemency so that she could be released in order to spend the final moments of her life with her family. The president accepted the petition, and she was released on 16 February 1995 and eventually died on 30 March that year. 1992: Koh Swee Beng, a Singaporean who killed a man who assaulted his foster father in 1988. He was convicted of murder and sentenced to hang in 1990. He lost his appeal against his death sentence in 1991 but was eventually granted clemency by President Wee Kim Wee on 13 May 1992 (two days before he was scheduled to be executed) and had his sentence commuted to life imprisonment. He was released from prison in September 2005 for good behaviour after serving at least two-thirds of his life sentence. 1998: Mathavakannan Kalimuthu, a Singaporean convicted of murder and sentenced to hang in 1996 along with his two friends. After losing their appeals in 1997, the three of them petitioned to President Ong Teng Cheong for clemency in 1998. The president accepted only Mathavakannan's plea so his sentence was commuted to life imprisonment; the other two had their pleas rejected and were subsequently executed. Mathavakannan was eventually released in 2012 after spending about 16 years in prison.
Light therapy treatments for the skin usually involve exposure to ultraviolet light. The exposures can be to a small area of the skin or over the whole body surface, as in a tanning bed. The most common treatment is with narrowband UVB, which has a wavelength of approximately 311–313 nanometers. Full body phototherapy can be delivered at a doctor's office or at home using a large high-power UVB booth. Tanning beds, however, generate mostly UVA light, and only 4% to 10% of tanning-bed light is in the UVB spectrum.
For morphological data, recent simulation studies suggest that parsimony may be less accurate than trees built using Bayesian approaches, potentially due to overprecision, although this has been disputed. Studies using novel simulation methods have demonstrated that differences between inference methods result from the search strategy and consensus method employed, rather than the optimization used. As in maximum parsimony, maximum likelihood will evaluate alternative trees. However it considers the probability of each tree explaining the given data based on a model of evolution. In this case, the tree with the highest probability of explaining the data is chosen over the other ones. In other words, it compares how different trees predict the observed data. The introduction of a model of evolution in ML analyses presents an advantage over MP as the probability of nucleotide substitutions and rates of these substitutions are taken into account, explaining the phylogenetic relationships of taxa in a more realistic way. An important consideration of this method is the branch length, which parsimony ignores, with changes being more likely to happen along long branches than short ones. This approach might eliminate long branch attraction and explain the greater consistency of ML over MP. Although considered by many to be the best approach to inferring phylogenies from a theoretical point of view, ML is computationally intensive and it is almost impossible to explore all trees as there are too many.
Sources: en.wikipedia.org
== External links == History of Discovery: The Tissue-Type Plasminogen Activator Story, Collen, D., Lijnen, H.R. Genentech Press Release 1982 Archived 2018-09-13 at the Wayback Machine Tissue Plasminogen Activator from the American Heart Association Widening the Window : Strategies to buy time in treating ischemic stroke - Scientific American (August 2005) Study expands window for effective stroke treatment - explained on YouTube
On 2 March, Hospital Moinhos de Vento, the largest of the hospitals within private networks in Rio Grande do Sul, had to rent a container in order to store the bodies of dead patients at the hospital, since the morgue in the hospital had also reached capacity. The collapse of the health system continued with daily records of hospitalizations in the city. In the Hospital de Clínicas, there were not enough specialized respirators. Along with this, health professionals had to choose which patients they should intubate, due to a lack of beds. Some patients went to be intubated at hospitals and would die there. At Hospital da Restinga, patients in the overcrowded emergency ward received care sitting in chairs due to the lack of stretchers. In some hospitals, some patients died in the hospital corridors due to a lack of beds. On 5 March, the state government also announced a fine of up to 4,000 real for those who did not wear masks, in an attempt to contain the spread of COVID-19. Melo, however, declared that the city would not apply the standard, saying he would not have people abide by the decision and that the usage of prevention methods would depend on the "conscience" of people. The municipality sought to disperse encampments at different points in the city, primarily in the Cidade Baixa neighborhood, considered a hotbed for petty crime and drug use. On the 10th and 14 March, two anti-government protests called for the reopening of local businesses and military intervention, respectively. They were held despite guidance against large gatherings.
The US Food and Drug Administration (FDA) has approved loxapine inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. A brief review of loxapine found no conclusive evidence that it was particularly effective in patients with schizophrenia. A subsequent systematic review considered that the limited evidence did not indicate a clear difference in its effects from other antipsychotics.
Sources: en.wikipedia.org
== Medical uses == Several treatment guidelines recommend adding ezetimibe in select high-risk persons in whom LDL goals cannot be achieved by maximally tolerated statin alone. Adding ezetimibe to statin treatment of high blood cholesterol has no effect on overall mortality or cardiovascular mortality, although it significantly reduces the risk of myocardial infarction and stroke. Combining ezetimibe with simvastatin had no effect on overall mortality but did lower the risk of heart attack or stroke in people with prior heart attack. Initiation of ezetimibe along with high-intensity statin therapy at the time of an acute coronary syndrome (ACS) event was associated with significantly better cholesterol reduction at day 7, 1-month, 3-months, and 1-year post-ACS event; which translated into significantly lower recurrent cardiovascular events (death from any cause, major ACS, non-fatal stroke, non-fatal myocardial infarction, and ischemic stroke) post the index event of ACS. Ezetimibe is indicated in the United States as an add-on to dietary measures to reduce levels of certain lipids in people with:
Due to their higher levels of androgen exposure during fetal development, the female hyenas are significantly more muscular and aggressive than their male counterparts; social-wise, they are of higher rank than the males, being dominant or dominant and alpha, and the females who have been exposed to higher levels of androgen than average become higher-ranking than their female peers. Subordinate females lick the clitorises of higher-ranked females as a sign of submission and obedience, but females also lick each other's clitorises as a greeting or to strengthen social bonds; in contrast, while all males lick the clitorises of dominant females, the females will not lick the penises of males because males are considered to be of lowest rank. The female spotted hyenas urinate, copulate and give birth through the clitoris since the urethra and vagina exit through the clitoral glans. This trait makes mating more laborious for the male than in other mammals, and also makes attempts to sexually coerce (physically force sexual activity on) females futile. Joan Roughgarden, an ecologist and evolutionary biologist, said that because the hyena's clitoris is higher on the belly than the vagina in most mammals, the male hyena "must slide his rear under the female when mating so that his penis lines up with [her clitoris]". In an action similar to pushing up a shirtsleeve, the "female retracts the [pseudo-penis] on itself, and creates an opening into which the male inserts his own penis". The male must practice this act, which can take a couple of months to successfully perform.
== Factors that affect the specific dynamic action == The specific dynamic action is increased by both aerobic training of sufficient duration and intensity or by anaerobic weight training. Caffeine intake at meals also has been shown to increase TEF by enhancing sympathetic arousal. However, these effects are marginal, amounting to 7-8 calories per hour. The primary determinants of daily TEF are the total caloric content of the meals and the macronutrient composition of the meals ingested. Meal frequency has little to no effect on TEF, assuming total calorie intake for the days are equivalent. Some studies suggest that SDA may be reduced in patients with obesity, especially those with insulin resistance, although research findings are mixed. A low TEF could potentially predispose to obesity by reducing energy expenditure and promoting a positive energy balance. Alternatively, the presence of a low TEF in many patients with obesity may be explained by insulin resistance, which can be related to excess dietary energy and vary in severity with the degree of obesity. Over time, chronic hyperinsulinemia could diminish the ability of cells to respond to insulin, promote adiposity and peripheral insulin resistance, and worsen the risk for type 2 diabetes. Some research shows that TEF may be more severely impaired in patients depending on the grade of insulin resistance, although some other studies have not reproduced that finding.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.